Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.40 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 9/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 9/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970302 | 1.00 | KDM4E (0.42) | KDM4EALDH1A1EGLN1EGLN2EGLN3 | |
| SCHEMBL1966106 | 0.89 | KDM4E (0.43) | KDM4EALDH1A1EGLN1EGLN2EGLN3 | |
| SCHEMBL1966102 | 0.89 | KDM4E (0.43) | KDM4EALDH1A1EGLN1EGLN2EGLN3 | |
| SCHEMBL27858864 | 0.86 | EGLN1 (0.47) | KDM4EALDH1A1EGLN1EGLN2EGLN3 | |
| SCHEMBL1219316 | 0.82 | EGLN1 (0.58) | KDM4EALDH1A1EGLN1EGLN2EGLN3 | |
| SCHEMBL3730844 | 0.81 | KDM4E (0.45) | KDM4EALDH1A1EGLN1EGLN2EGLN3 | |
| SCHEMBL1966099 | 0.79 | KDM4E (0.44) | KDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL1987167 | 0.77 | EGLN1 (0.42) | KDM4EALDH1A1EGLN1EGLN3SMN1; SMN2 | |
| SCHEMBL1967710 | 0.76 | EGLN3 (0.37) | ALDH1A1EGLN1EGLN2EGLN3ITGA4 | |
| SCHEMBL1967712 | 0.76 | EGLN3 (0.37) | ALDH1A1EGLN1EGLN2EGLN3ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334682-B1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN INC (US) | 2017-10-04 | — | — | EP | claimed |
| US-8217043-B2 | Compounds and methods for their use | FIBROGEN, INC. (US) | 2012-07-10 | — | — | US | claimed |
| EP-2334682-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | Fibrogen, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010022240-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | claimed |
| EP-2334682-B1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN INC (US) | 2017-10-04 | — | — | EP | disclosed |
| CN-102264740-B | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators | FIBROGEN, INC. (US) | 2014-10-15 | — | — | CN | disclosed |
| US-8217043-B2 | Compounds and methods for their use | FIBROGEN, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| CN-102264740-A | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators | — | 2011-11-30 | — | — | CN | disclosed |
| EP-2334682-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | Fibrogen, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010022240-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | HIF1AN, HIF1A, EGLN3 | KDM4E 471/4885ALDH1A1 268/4885EGLN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.